ArticlePloS one2013
Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023Pooled it
- Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis.Journal of molecular medicine (Berlin, Germany) · 2022Pooled it
- Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management.Journal of cellular and molecular medicine · 2024Review
- Overexpression of Nucleolin and Associated Genes in Prostate Cancer.International journal of molecular sciences · 2022Article
- The Synergistic Role of Tip α, Nucleolin and Ras in Helicobacter pylori Infection Regulates the Cell Fate Towards Inflammation or Apoptosis.Current microbiology · 2021Article
- Targeting the oncogenic TBX3:nucleolin complex to treat multiple sarcoma subtypes.American journal of cancer research · 2021Article
- Article
- The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as Targets.Frontiers in oncology · 2020Review
- Investigation of Different Molecular Weight Fucoidan Fractions Derived from New ZealandMarine drugs · 2018Article
- Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.Cancer investigation · 2018Article
- Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.Oncotarget · 2016Article
- Nuclear Protein C23 on the Cell Surface Plays an Important Role in Activation of CXCR4 Signaling in Glioblastoma.Molecular neurobiology · 2015Article
- Human anti-nucleolin recombinant immunoagent for cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Cell surface protein C23 affects EGF-EGFR induced activation of ERK and PI3K-AKT pathways.Journal of molecular neuroscience : MN · 2015Article
- Non-apoptotic cell death associated with perturbations of macropinocytosis.Frontiers in physiology · 2015Review
- Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.Oncotarget · 2014Article
- Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy.Diagnostic pathology · 2014Article
- Ras and autophagy in cancer development and therapy.Oncotarget · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ErbB receptors, Ras proteins and nucleolin are major contributors to malignant transformation. The pleiotropic protein nucleolin can bind to both Ras protein and ErbB receptors. Previously, we have demonstrated a crosstalk between Ras, nucleolin and the ErbB1 receptor. Activated Ras facilitates nucleolin interaction with ErbB1 and stabilizes ErbB1 levels. The three oncogenes synergistically facilitate anchorage independent growth and tumor growth in nude mice. METHODOLOGY/PRINCIPAL
findingsIn the present study we used several cancer cell lines. The effect of Ras and nucleolin inhibition was determined using cell growth, cell death and cell motility assays. Protein expression was determined by immunohistochemistry. We found that inhibition of Ras and nucleolin reduces tumor cell growth, enhances cell death and inhibits anchorage independent growth. Our results reveal that the combined treatment affects Ras and nucleolin levels and localization. Our study also indicates that Salirasib (FTS, Ras inhibitor) reduces cell motility, which is not affected by the nucleolin inhibitor. CONCLUSIONS/SIGNIFICANCE: These results suggest that targeting both nucleolin and Ras may represent an additional avenue for inhibiting cancers driven by these oncogenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.